spacer
home > ebr > summer 2003 > are patents the beating heart of your boardroom?
PUBLICATIONS
European Biopharmaceutical Review

Are Patents the Beating Heart of your Boardroom?

Most companies do not yet understand that intellectual property (IP) is a lifeline in the brutally competitive world we now face. If you don't believe me here is a quick and easy way to determine the level of IP knowledge in your organisation.

Ask around your colleagues, or even better your boardroom, this simple question: how many years can a court enforce your patents, copyright and trademarks upon other companies?


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Ian Harvey, Chief Executive Officer of BTG plc and Chairman of the Government's Intellectual Property Advisory Committee

Ian Harvey is the CEO of BTG, a global technology commercialisation company. He is also Chairman of both the Intellectual Property Institute and the DTI's Intellectual Property Advisory Committee. He joined BTG in 1985 as Chief Executive having spent 10 years with Vickers and Laporte Industries and seven years with the World Bank. Between 1988 and 1993 he served as a member of the Prime Minister's Advisory Council on Science and Technology.

Ian is a Fellow of Nottingham University (1994), and a Member of the Advisory Panel for Science and Technology Policy Research of Sussex University (SPRU) since 1989. He has an MA in Mechanical Sciences from Cambridge University and an MBA from Harvard University.

spacer
Ian Harvey
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Senior Vice President Dr. David Daniel Honored in PharmaVOICE 100

Philadelphia, PA – August 1, 2019: Signant Health (formerly CRF Health and Bracket) today announces that its Senior Vice President, Dr. David Daniel, has been selected by PharmaVOICE as one of the top 100 most inspiring people within the life sciences sector. Dr. Daniel was selected from a large cross section of established professionals in the life sciences industry for his passion to continually improve the way in which science, technology and service interact. This honor swiftly follows another recent mark of distinction for Dr. Daniel, having been co-awarded the 2019 ISCDD Scientific Leadership Award.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement